TP53 and cancer: Two somatic molecular genetic alterations are minimally required for cancer development in this population, loss of the wild-type BRCA allele and, in a majority of cases, mutational inactivation of the TP53 gene [20], both of which may be used to search for preclinical genetic evidence of ovarian tumorigenesis.